When administered to individuals affected by diabetes, these drugs inhibit the renal reabsorption of glucose by blocking the sodium-coupled glucose transporter 2 (SGLT2) selectively expressed in the proximal tubule (Figure 3). This evidence concerns the gene SLC5A2 and diabetes mellitus.